

30880-ANSWERING REVIEWERS

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 30880

Title: Factors influencing the response to ingenol mebutate therapy for actinic keratosis of face and scalp: a cohort study

Reviewer's code: 00646569

COMMENTS TO AUTHORS

You stated that ethics committee approval was waived, I think it is a prerequisite for a study involving an individual and to report it. You must get approval for an observational study as well. You can discuss the advantages of ingenol mebutate therapy for actinic keratosis in comparison to other therapeutic choices like imiquimod, 5-fluorouracil.

Response:

We send you ethics committee approval.

Ingenol mebutate therapy for actinic keratosis is better than other therapeutic choices like imiquimod, 5-fluorouracil because the short time of applications (only three times) and patients compliance.



BAISHIDENG PUBLISHING GROUP INC

7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

Reviewer's code: 00646460

COMMENTS TO AUTHORS

This is an interesting study regarding the use of ingenol mebutate therapy for actinic keratosis of face and scalp, and the factors which may affect the treatment response. The study was well-performed, the results are novel and interesting, and the findings should be clinically relevant and useful.

Response:

Thank you for your comments.